XOMA
XOMA Royalty Corporation
NASDAQ: XOMA · HEALTHCARE · BIOTECHNOLOGY
$41.75
-0.73% today
Updated 2026-06-05
Market cap
$522.84M
P/E ratio
26.55
P/S ratio
10.77x
EPS (TTM)
$1.57
Dividend yield
—
52W range
$22 – $43
Volume
0.2M
WallStSmart proprietary scores
49
out of 100
Grade: C
Sell
Investment rating
7.3
Growth
B+5.5
Quality
C+6.5
Profitability
B4.3
Valuation
C4/9
Piotroski F-Score
Moderate
-4.8
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$39.00
-6.59%
12-Month target
$24.15
-42.16%
Intrinsic (DCF)
$19.29
Margin of safety
-20.63%
0 Strong Buy1 Buy3 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 69.60% — above average
+ ROE 27.91% — strong efficiency
+ Free cash flow $6.04M — positive
Risks
- Altman Z -4.80 — distress zone
- Revenue declining -22.60% QoQ
- 20.63% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $6.03M | $4.76M | $28.49M | $52.15M | $48.55M |
| Net income | $-17.10M | $-40.83M | $-13.82M | $31.71M | $4.46M |
| EPS | — | — | — | — | $1.57 |
| Free cash flow | $-36.13M | $-18.18M | $-13.77M | $-17.85M | $6.04M |
| Profit margin | -283.79% | -858.15% | -48.52% | 60.81% | 69.60% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-21 | WYSZOMIERSKI, JACK L | Buy | 3,586 | — |
| 2026-05-21 | PERRY, MATTHEW D | Buy | 3,586 | — |
| 2026-05-21 | LIMBER, JOSEPH M | Buy | 3,586 | — |
Peer comparison
Smart narrative
XOMA Royalty Corporation trades at $41.75. representing a P/E of 26.55x trailing earnings. Our Smart Value Score of 49/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -4.80, it sits in the distress. TTM revenue stands at $48.55M. with profit margins at 69.60%. Our DCF model estimates intrinsic value at $19.29.
Frequently asked questions
What is XOMA Royalty Corporation's stock price?
XOMA Royalty Corporation (XOMA) trades at $41.75, on a P/E of 26.6x and a P/S of 10.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is XOMA Royalty Corporation overvalued?
XOMA Royalty Corporation carries a Smart Value Score of 49/100 (Grade C), which we rate Sell. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $19.29 against the $41.75 price, so on cash flow terms the market is paying a premium for XOMA Royalty Corporation's growth. The Sell rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of XOMA Royalty Corporation (XOMA)?
The 12-month analyst consensus target is $39.00, about 6.6% below the current $41.75. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of XOMA Royalty Corporation (XOMA)?
Our DCF model estimates intrinsic value at $19.29, a -20.6% margin of safety versus today's $41.75. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is XOMA Royalty Corporation's revenue?
XOMA Royalty Corporation's trailing twelve-month revenue is $48.55M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
XOMA Royalty Corporation's Altman Z-Score is -4.80, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio10.77x
ROE27.91%
Beta0.90
50D MA$38.55
200D MA$32.70
Shares out0.01B
Float0.00B
Short ratio—
Avg volume0.2M
Performance
1 week+0.00%
1 month+0.21%
3 months+59.55%
YTD+58.29%
1 year—
3 years—
5 years—